Novartis India, a Mumbai based Rs. 625
crore MNC, has posted better growth in top line as well as bottom line
during the second quarter ended September 2010. Its net profit increased
by 22 per cent to Rs. 40.56 crore from Rs. 33.26 crore in the similar period of last year and its net sales increased by 14.5 per cent to Rs. 184.91 core from Rs. 161.54 crore. Earnings before interest, depreciation and taxation went up by 17.9 per cent to Rs. 60.17 crore from Rs. 51.02 crore. The earning per share, for the quarter, worked out to Rs. 12.69 as against Rs. 10.40 in the lat period. The face value of share is Rs. 5 each.

Its pharmaceutical sales increased to Rs. 129.03 crore from Rs. 113.50 crore, a growth of 13.7 per cent during the second quarter of FY11 and its generic sales touched to Rs. 11.36 crore as against Rs. 9.97 crore. The sales of OTC products increased to Rs. 26.48 crore from Rs. 20.70 crore.

For the first half ended September 2010, Novartis reported net sales of Rs. 353.19 crore as compared to Rs. 314.72 crore, representing a growth of 12.2 per cent. Its net profit improved by 10.9 per cent to Rs. 72.09 crore from Rs. 65.02 crore. It pharmaceutical sales in first half went up by 11.1 per cent to Rs. 251.22 crore and that of generic increased by 8.7 per cent to Rs. 22.56 crore from Rs. 20.76 crore. Sales from OTC products reached at Rs. 46.40 crore from Rs. 37.65 crore in the corresponding half of last year.